Suzhou Huiliao Biotech Appoints Dr. Zhang Lixia as Vice President & Head of Drug Registration.

On September 29, 2022, Suzhou Huizhi Biomedical Technology Co., Ltd. announced the appointment of Dr. Zhang Lixia as the Vice President of the company, responsible for drug registration related work.

Dr. Zhang Lixia, Vice President of Huili Biotechnology:

Summary of Education and Career Experience:

Dr. Zhang Lixia graduated from Wuhan University with a major in Chemistry and Molecular Science. Studied under Academician Zhou Xiang,

The main research direction is the recognition and functional regulation of nucleic acid structures by small molecules, and the development of nucleic acid targeted drugs through the recognition and functional regulation of nucleic acid structures by small molecules.

The research work during the doctoral period won the first prize of Hubei Provincial Natural Science Award.

I have worked in pharmaceutical research institutes, biopharmaceutical companies, and medical science popularization companies from 1997 to 2021, with over 20 years of work experience in the field of biomedicine.

Since entering the pharmaceutical industry, Dr. Zhang Lixia has been engaged in research, development, and registration of chemical generic drugs, chemical innovative drugs, medical science popularization, and small nucleic acid innovative drugs. I have a deep understanding of the entire process of new drug development and the ability to control key nodes in new drug development. I have helped the company successfully obtain the IND clinical approval for the first small nucleic acid drug in China.

Dr. Zhong Tianyi, the founder and CEO of Huili Biotechnology, warmly welcomes Dr. Zhang Lixia to join Suzhou Huili Biopharmaceutical Technology Co., Ltd. Dr. Zhang Lixia has rich experience in new drug research and registration, and her joining will greatly improve the development progress and registration success rate of Huili's nucleic acid drugs. We look forward to Dr. Zhang Lixia's leadership in rapidly advancing the company's nucleic acid drug research and development, and helping Huili move towards its goal of becoming a leading RNA drug enterprise with international competitiveness

Dr. Zhang Lixia stated that nucleic acid drugs have opened up new therapeutic fields, breaking through the limitations of existing clinical treatments. She believes that nucleic acid drugs can solve more clinical needs in the future. I am very honored to join Huili. Huili has a complete mRNA raw material drug and carrier development technology platform. I hope to rely on Huili's complete technology platform to help the company accelerate the speed of nucleic acid drug launch, solve clinical needs, and alleviate patient pain.